Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Stigmasterol.
Stigmasterol is a phytosterol that modulates cholesterol metabolism by inhibiting intestinal absorption and exhibits anti-inflammatory properties through the inhibition of pro-inflammatory cytokines and matrix metalloproteinases.
5280794
412.7 g/mol
8.6
(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Stigmasterol across standard consumer modalities.
High lipophilicity and crystalline structure may result in poor dissolution rates and low bioavailability without the inclusion of surfactants or lipid carriers.
The hydrophobic nature and high melting point of stigmasterol can lead to recrystallization and a gritty texture within the pectin or gelatin matrix.
Significant payload limitations exist due to the high effective dose required for cholesterol management, making it difficult to incorporate into thin-film polymers.
Ready to launch a product featuring Stigmasterol? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Stigmasterol extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Stigmasterol payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation